LINCOLN PHARMACEUTICALS
|
|
BOM : 531633     NSE : LINCOLN     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Dec 13,2024 |
Price(EOD): ₹ 927.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,855.70 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
LINCOLN PHARMACEUTICALS | -3.1% | 41.4% | 39.4% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 0.8% | 45.4% |
CIPLA | -1.5% | -5.1% | 20.3% |
DR REDDYS LABORATORIES | -0.7% | -1.3% | 13.8% |
ZYDUS LIFESCIENCES | -0.5% | 3% | 54.1% |
DIVIS LABORATORIES | -1.4% | 1.2% | 62% |
MANKIND PHARMA | 0% | 0.5% | 38.1% |
TORRENT PHARMACEUTICALS | 0.4% | 6.3% | 60.1% |
LUPIN | -1.5% | -0.6% | 72.3% |
FUNDAMENTAL ANALYSIS OF LINCOLN PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF LINCOLN PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
19.23
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 96.64 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 3.13
P/B Calculated based on Book Value of Rs 592.84 Cr
[Latest Year - Mar2024 - Consolidated Results ] 3.11
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 597.44 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
215% 132% 148% |
SHARE PRICE MOMENTUM OF LINCOLN PHARMACEUTICALS
LINCOLN PHARMACEUTICALS vs SENSEX
DEBT OF LINCOLN PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
0 0 0 - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF LINCOLN PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF LINCOLN PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
9.46% 24.85% 18% 11.23% |
3.35% -8.89% -5.65% -4.78% |
QtrlyTrend |
2 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
LINCOLN PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MIDSMALLCAP | 0% | 4.7% | 37.1% |
S&P BSE SMALL CAP | -0.2% | 4.9% | 38.6% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE HEALTHCARE | -1% | 1.4% | 45.2% |
You may also like the below Video Courses
FAQ about LINCOLN PHARMACEUTICALS
Is LINCOLN PHARMACEUTICALS good for long term investment?
As on Dec 13,2024, the Fundamentals of LINCOLN PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of LINCOLN PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is LINCOLN PHARMACEUTICALS UnderValued or OverValued?
As on Dec 13,2024, LINCOLN PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of LINCOLN PHARMACEUTICALS ?
As on Dec 13,2024, the Intrinsic Value of LINCOLN PHARMACEUTICALS is Rs. 374.56 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 294.51
Fair Value [Median EV / Sales Model] : Rs. 400.16
Fair Value [Median Price / Sales Model] : Rs. 374.56
Estimated Median Fair Value of LINCOLN PHARMACEUTICALS : Rs. 374.56
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.